Literature DB >> 33837205

SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2.

Gaurav A Mehta1,2, Steven P Angus3, Christen A Khella1,2, Kevin Tong2,4, Pooja Khanna1,2, Shelley A H Dixon3, Michael P Verzi2,4, Gary L Johnson5, Michael L Gatza6,7.   

Abstract

Dysregulation of PI3K/Akt signaling is a dominant feature in basal-like or triple-negative breast cancers (TNBC). However, the mechanisms regulating this pathway are largely unknown in this subset of aggressive tumors. Here we demonstrate that the transcription factor SOX4 is a key regulator of PI3K signaling in TNBC. Genomic and proteomic analyses coupled with mechanistic studies identified TGFBR2 as a direct transcriptional target of SOX4 and demonstrated that TGFBR2 is required to mediate SOX4-dependent PI3K signaling. We further report that SOX4 and the SWI/SNF ATPase SMARCA4, which are uniformly overexpressed in basal-like tumors, form a previously unreported complex that is required to maintain an open chromatin conformation at the TGFBR2 regulatory regions in order to mediate TGFBR2 expression and PI3K signaling. Collectively, our findings delineate the mechanism by which SOX4 and SMARCA4 cooperatively regulate PI3K/Akt signaling and suggest that this complex may play an essential role in TNBC genesis and/or progression.

Entities:  

Year:  2021        PMID: 33837205     DOI: 10.1038/s41523-021-00248-2

Source DB:  PubMed          Journal:  NPJ Breast Cancer        ISSN: 2374-4677


  73 in total

1.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

Review 2.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

3.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

Authors:  Lisa A Carey; Charles M Perou; Chad A Livasy; Lynn G Dressler; David Cowan; Kathleen Conway; Gamze Karaca; Melissa A Troester; Chiu Kit Tse; Sharon Edmiston; Sandra L Deming; Joseph Geradts; Maggie C U Cheang; Torsten O Nielsen; Patricia G Moorman; H Shelton Earp; Robert C Millikan
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

4.  An E2F1-dependent gene expression program that determines the balance between proliferation and cell death.

Authors:  Timothy C Hallstrom; Seiichi Mori; Joseph R Nevins
Journal:  Cancer Cell       Date:  2008-01       Impact factor: 31.743

5.  Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.

Authors:  M Piccart; G N Hortobagyi; M Campone; K I Pritchard; F Lebrun; Y Ito; S Noguchi; A Perez; H S Rugo; I Deleu; H A Burris; L Provencher; P Neven; M Gnant; M Shtivelband; C Wu; J Fan; W Feng; T Taran; J Baselga
Journal:  Ann Oncol       Date:  2014-09-17       Impact factor: 32.976

6.  A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations.

Authors:  Yiqun Zhang; Patrick Kwok-Shing Ng; Melanie Kucherlapati; Fengju Chen; Yuexin Liu; Yiu Huen Tsang; Guillermo de Velasco; Kang Jin Jeong; Rehan Akbani; Angela Hadjipanayis; Angeliki Pantazi; Christopher A Bristow; Eunjung Lee; Harshad S Mahadeshwar; Jiabin Tang; Jianhua Zhang; Lixing Yang; Sahil Seth; Semin Lee; Xiaojia Ren; Xingzhi Song; Huandong Sun; Jonathan Seidman; Lovelace J Luquette; Ruibin Xi; Lynda Chin; Alexei Protopopov; Thomas F Westbrook; Carl Simon Shelley; Toni K Choueiri; Michael Ittmann; Carter Van Waes; John N Weinstein; Han Liang; Elizabeth P Henske; Andrew K Godwin; Peter J Park; Raju Kucherlapati; Kenneth L Scott; Gordon B Mills; David J Kwiatkowski; Chad J Creighton
Journal:  Cancer Cell       Date:  2017-05-18       Impact factor: 31.743

Review 7.  PI3K and cancer: lessons, challenges and opportunities.

Authors:  David A Fruman; Christian Rommel
Journal:  Nat Rev Drug Discov       Date:  2014-02       Impact factor: 84.694

Review 8.  Oncogenic PI3K and its role in cancer.

Authors:  Yardena Samuels; Kajsa Ericson
Journal:  Curr Opin Oncol       Date:  2006-01       Impact factor: 3.645

9.  Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer.

Authors:  Gaurav A Mehta; Joel S Parker; Grace O Silva; Katherine A Hoadley; Charles M Perou; Michael L Gatza
Journal:  Breast Cancer Res Treat       Date:  2017-02-07       Impact factor: 4.872

10.  PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.

Authors:  Elena López-Knowles; Sandra A O'Toole; Catriona M McNeil; Ewan K A Millar; Min R Qiu; Paul Crea; Roger J Daly; Elizabeth A Musgrove; Robert L Sutherland
Journal:  Int J Cancer       Date:  2010-03-01       Impact factor: 7.396

View more
  1 in total

1.  Identification of key genes involved in tamoxifen-resistant breast cancer using bioinformatics analysis.

Authors:  Xiaopeng Wang; Shixia Wang
Journal:  Transl Cancer Res       Date:  2021-12       Impact factor: 1.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.